124 related articles for article (PubMed ID: 37207875)
1. Constructing an individualized surveillance framework for nasopharyngeal carcinoma based on a dynamic risk-adapted approach.
Lu T; Xu H; Huang W; Zong J; Pan C; Huang C; Xiao Y; Chen B; Li J; Pan J; Lin S; Guo F; Guo Q
Radiother Oncol; 2023 Aug; 185():109716. PubMed ID: 37207875
[TBL] [Abstract][Full Text] [Related]
2. Stage-dependent conditional survival and failure hazard of non-metastatic nasopharyngeal carcinoma after intensity-modulated radiation therapy: Clinical implications for treatment strategies and surveillance.
Wang J; Huang X; Sun S; Wang K; Qu Y; Chen X; Wu R; Zhang Y; Liu Q; Zhang J; Luo J; Xiao J; Gao L; Xu G; Hu C; Li YX; Yi J
Cancer Med; 2021 Jun; 10(11):3613-3621. PubMed ID: 33960136
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a web-based calculator to predict individualized conditional risk of site-specific recurrence in nasopharyngeal carcinoma: Analysis of 10,058 endemic cases.
Wu CF; Lv JW; Lin L; Mao YP; Deng B; Zheng WH; Wen DW; Chen Y; Kou J; Chen FP; Yang XL; Zheng ZQ; Li ZX; Xu SS; Ma J; Sun Y
Cancer Commun (Lond); 2021 Jan; 41(1):37-50. PubMed ID: 33270990
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era.
Li PJ; Mo HY; Luo DH; Hu WH; Jin T
Oral Oncol; 2018 Oct; 85():95-100. PubMed ID: 30220326
[TBL] [Abstract][Full Text] [Related]
5. Retrospective Analysis of Induction Chemotherapy plus Concurrent Chemoradiotherapy under Intensity-Modulated Radiotherapy Mode for Locally Advanced Nasopharyngeal Carcinoma.
Liao K; Tao HY; Zhan ZJ; Qiu WZ; Zheng RH
Oncol Res Treat; 2021; 44(11):602-612. PubMed ID: 34601467
[TBL] [Abstract][Full Text] [Related]
6. Survival benefit of induction chemotherapy for locally advanced nasopharyngeal carcinoma: prognosis based on a new risk estimation model.
Liu W; Yu B; Luo Y; Li J; Yuan X; Wu S; Liang B; Lv Z; Li Y; Peng X; Lu J; Peng X; Liu X
BMC Cancer; 2021 May; 21(1):639. PubMed ID: 34051750
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial.
Ke LR; Xia WX; Qiu WZ; Huang XJ; Yang J; Yu YH; Liang H; Liu GY; Ye YF; Xiang YQ; Guo X; Lv X
BMC Cancer; 2017 Feb; 17(1):134. PubMed ID: 28202000
[TBL] [Abstract][Full Text] [Related]
8. Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials.
Kong L; Zhang Y; Hu C; Guo Y; Lu JJ
Cancer; 2017 Jun; 123(12):2258-2267. PubMed ID: 28192641
[TBL] [Abstract][Full Text] [Related]
9. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.
Lv X; Cao X; Xia WX; Liu KY; Qiang MY; Guo L; Qian CN; Cao KJ; Mo HY; Li XM; Li ZH; Han F; He YX; Liu YM; Wu SX; Bai YR; Ke LR; Qiu WZ; Liang H; Liu GY; Miao JJ; Li WZ; Lv SH; Chen X; Zhao C; Xiang YQ; Guo X
Lancet Oncol; 2021 May; 22(5):716-726. PubMed ID: 33857411
[TBL] [Abstract][Full Text] [Related]
10. Nedaplatin-based chemotherapy or cisplatin-based chemotherapy combined with intensity-modulated radiotherapy achieve similar efficacy for stage II-IVa nasopharyngeal carcinoma patients.
Deng C; Zhang N; Jiang S; Zhang H; Ma J; Zou W; Liu X; Hu C; Hou T
Sci Rep; 2022 Jul; 12(1):11978. PubMed ID: 35831424
[TBL] [Abstract][Full Text] [Related]
11. Volumetric modulated arctherapy for locally advanced nasopharyngeal carcinoma: Clinical efficacy and late toxicity.
Hommadi M; N'da G; Bertrand C; Randriamaroson N; Benlemlih M; Mosse WBA; El Mejjaoui S; Kebdani T; El Kacemi H; Benjaafar N
Cancer Radiother; 2022 May; 26(3):433-439. PubMed ID: 34366239
[TBL] [Abstract][Full Text] [Related]
12. Retrospective Analysis of the Survival Benefit of Induction Chemotherapy in Stage IVa-b Nasopharyngeal Carcinoma.
Lan XW; Zou XB; Xiao Y; Tang J; OuYang PY; Su Z; Xie FY
PLoS One; 2016; 11(8):e0160758. PubMed ID: 27509025
[TBL] [Abstract][Full Text] [Related]
13. Analysis of intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma.
Wu S; Quan R; Han L; Zhang H; Zhang B; Xu G; Li X
Medicine (Baltimore); 2020 Jul; 99(30):e21325. PubMed ID: 32791728
[TBL] [Abstract][Full Text] [Related]
14. Definitive intensity-modulated radiation therapy for nasopharyngeal carcinoma: long-term outcome of a multicenter prospective study.
Wang R; Wu F; Lu H; Wei B; Feng G; Li G; Liu M; Yan H; Zhu J; Zhang Y; Hu K
J Cancer Res Clin Oncol; 2013 Jan; 139(1):139-45. PubMed ID: 22986812
[TBL] [Abstract][Full Text] [Related]
15. Tumor residue in patients with stage II-IVA nasopharyngeal carcinoma who received intensity-modulated radiation therapy: development and validation of a prediction nomogram integrating postradiotherapy plasma Epstein-Barr virus deoxyribonucleic acid, clinical stage, and radiotherapy dose.
Huang YY; Zhou JY; Zhan ZJ; Ke LR; Xia WX; Cao X; Cai ZC; Deng Y; Chen X; Zhang LL; Huang HY; Guo X; Lv X
BMC Cancer; 2023 May; 23(1):410. PubMed ID: 37149594
[TBL] [Abstract][Full Text] [Related]
16. A multicenter retrospective analysis of patients with nasopharyngeal carcinoma treated in IMRT era from a nonendemic population: Turkish Society for Radiation Oncology Head and Neck Cancer Group Study (TROD 01-001).
Yildirim HC; Kupik GE; Mustafayev TZ; Berber T; Yavuz B; Cetinayak O; Akagunduz O; Bıcakcı BC; Arslan SA; Soykut ED; Gundog M; Figen M; Teke F; Canyilmaz E; Birgi SD; Duzova M; İgdem S; Abakay CD; Atasoy B; Kaydihan N; Parvizi M; Uslu GH; Saginc H; Akman F; Ozyar E
Head Neck; 2023 May; 45(5):1194-1205. PubMed ID: 36854873
[TBL] [Abstract][Full Text] [Related]
17. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
Wei Z; Zhang Z; Luo J; Li N; Peng X
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Use of Nimotuzumab in Combination With Intensity-Modulated Radiotherapy and Chemotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: Experience of a Single Institution.
Fangzheng W; Chuner J; Zhiming Y; Tongxin L; Fengqin Y; Lei W; Bin L; Fujun H; Ming C; Weifeng Q; Zhenfu F
Oncol Res; 2018 Mar; 26(2):277-287. PubMed ID: 29046165
[TBL] [Abstract][Full Text] [Related]
19. Sequential induction chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three-year report of a phase II, single center, randomized, non-inferiority trial.
Yang Z; Cai Z; Cai Q; Hong Y; Zhang C; Huang K; Lin Z; Li M
Cancer Med; 2021 Jun; 10(12):3886-3895. PubMed ID: 33955190
[TBL] [Abstract][Full Text] [Related]
20. Nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: clinical outcomes and patterns of failure among subsets of 8th AJCC stage IVa.
Huang CL; Guo R; Li JY; Xu C; Mao YP; Tian L; Lin AH; Sun Y; Ma J; Tang LL
Eur Radiol; 2020 Feb; 30(2):816-822. PubMed ID: 31650266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
